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Abstract
Dysregulated tonic pupil size has been reported in Autism Spectrum Disorder (ASD). Among the
possible sources of this dysregulation are disruptions in the feedback loop between norepinephrine
(NE) and hypothalamic systems. In the current study, we examined afternoon levels of salivary
alpha-amylase (sAA, a putative correlate of NE) and cortisol (used to assess stress-based
responses) in two independent samples of children with ASD. We found a larger pupil size and
lower sAA levels in ASD, compared to typical and clinical age-matched controls. This was
substantiated at the individual level, as sAA levels were strongly correlated with tonic pupil size.
Relatively little diurnal variation in sAA taken in the home environment in the ASD group was
also observed, while typical controls showed a significant linear increase throughout the day.
Results are discussed in terms of potential early biomarkers and the elucidation of underlying
neural dysfunction in ASD.
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The past 15 to 20 years have seen an increase in the prevalence of Autism Spectrum
Disorder (ASD) (Fombonne, 1999; Gernsbacher, Dawson, & Goldsmith, 2005). The Center
for Disease Control and Prevention (CDC, 2012) has estimated the occurrence of ASD to be
as high as 1 out of 88 births, making it one of the highest-incidence childhood
neurodevelopmental disorders. As a result, ASD has been classified by the CDC as an
urgent public health priority and have identified two interrelated goals to address this
disorder: First to identify biomarkers that can serve to improve early detection of ASD, and
second to investigate the physiological signatures of the disorder that might ultimately lead
to greater insight into the neurodevelopmental processes that underlie ASD.
Characteristically, ASD has a late diagnosis, being diagnosed on average between 5 and 9
years of age (Hertz-Picciotto & Delwiche, 2009). The late diagnosis impedes the use of
early behavioral and educational interventions when they appear to be most efficacious (i.e.,
before 24 months of age; Dawson, 2010; Harris & Handleman, 2000). Behavioral
assessments for administration before 24 months of age have been developed and are
commonly used to identify ASD, but due to the due to the subtle and heterogeneous nature
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of ASD behavioral profiles at that early age (Pierce, Glatt, Liptak, & McIntyre, 2009;
Zwaigenbaum et al., 2009) these measures have been criticized (Barbaro & Dissanayake,
2009; Yirmiya & Charman, 2010) as lacking the sensitivity and specificity required for
universal screening of the disorder. These problems highlight the desirability of biomarkers
with high sensitivity and specificity to ASD into early detection and screening protocols.
Because some of the neural impairments commonly found in ASD may be present during
the prenatal period (Bauman & Kemper, 2005) it seems reasonable to posit the presence of a
systemic physiological indicator of these impairments well before the common age of
diagnosis. Such an indicator would be advantageous for early screening and detection, and
could conceivably address the requisite need to obtain a better understanding of the early
neurodevelopmental processes that occur in ASD (Dawson, 2010; Ratajczak, 2011;
Zwaigenbaum, 2010).
Rationale for the Current Study
Previous studies have found dysregulated tonic pupil responses to consistently distinguish
children with ASD from controls. Rubin found a smaller pupil size to a dark stimulus and a
larger pupil size to a light stimulus in ASD compared to controls (Rubin, 1961). Anderson
and Colombo (2009) subsequently found two- to five-year-old children with ASD to have a
larger tonic pupil size to a light stimulus (5.1 lx) than age-matched controls. Fan et al.
(2009) demonstrated alterations in pupil latency, amplitude and velocity to light stimuli in
addition to dysregulated pupil responses to both light and dark stimulation in ASD. Finally,
Martineau et al. (2011) found a smaller pupil response to a dark stimulus (0.0 lx) in ASD
compared to controls. It is worth noting that Martineau et al (2011) interpreted their results
as being incongruent with previous findings, but given that the typical response to a light
stimulus is a decrease in pupil size and increase to a dark stimulus their findings reported in
these studies are quite consistent with the general finding of pupillary dysregulation in ASD.
These findings are also congruent with other ANS investigations where altered resting and
reflex autonomic responses such as cardiac and electrodermal activity (Bal et al., 2009;
Ming, Julu, Brimacombe, Connor, & Daniels, 2005; Van Hecke et al., 2009), decreased
sleep (Giannotti et al., 2008; Honomichl, Goodlin-Jones, Burnham, Gaylor, & Anders, 2002;
Oyane & Bjorvatn, 2005), and blunted pain perception (Baranek & Berkson, 1994; Kientz &
Dunn, 1997) in ASD. The current study sought to replicate and extend previous studies by
examining the neural systems responsible for the control of pupil size in young children with
ASD.
We view tonic pupil size as an exemplar of the type of measurement that would address the
CDC priorities described above. Tonic pupil size is accessible before 24 months of age
(Boev et al., 2005; Robinson & Fielder, 1990), and the potential sources of neurological
dysfunction in pupil size are finite (Beatty & Lucero-Wagoner, 2000). This measure also has
the advantage of being more sensitive to small-scale changes and small sample sizes than
other autonomic measures such as heart-rate and electrodermal responses (Tursky, Shapiro,
Crider, & Kahneman, 1969). The tonic size of the pupil is obtained by measuring reflexive
pupillary responses to changes in luminance and accommodation efforts. Such measures
must be independent of cognitive load, and change with alertness and diurnal variation.
Neuroanatomy of the pupillary system
Noted above, the neural pathways that regulate tonic pupil size are finite and limited;
optimal pupillary function is determined by a balance of inhibitory and excitatory activity
within the sympathetic and parasympathetic components of the ANS (Beatty & Lucero-
Wagoner, 2000). The two most important components of the pupillary system are the
norepinephrine (NE) [locus coeruleus (LC), ventrolateral medulla (A1), and ventrolateral
pons (A5)] and hypothalamic systems (lateral and posterior hypothalamus); these systems
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provide both inhibitory and excitatory influences that are mediated by NE, and histamine
and orexin, respectively (Guyenet, 1991; Hou, Langley, Szabadi, & Bradshaw, 2007;
Stenberg, 2007; Szabadi & Bradshaw, 1996). As such, alterations in this balance can affect
resting and reflex autonomic activity, sleep-wake cycle patterns, and the processing of
incoming information, all of which have been found to be impaired in individuals with ASD
as presented above. Therefore, dysregulated tonic pupil responses, along with other ANS
mediated dysfunction in ASD, may be traced to perturbations in one or both of these
systems—The role of the hypothalamic pituitary adrenal axis (HPA) is widely known and
has been examined in depth (Corbett, Mendoza, Abdullah, Wegelin, & Levine, 2006;
Corbett, Mendoza, Wegelin, Carmean, & Levine, 2008; Spratt et al., 2012), but the case for
the involvement of NE in ASD is less familiar; we have briefly reviewed the NE-system in
the sections that follow.
The NE-system and ASD—A relatively large literature exists on NE and ASD. Six
studies have shown that measures of plasma NE are elevated in ASD (Cook, 1990;
Israngkun, Newman, & Patel, 1986; Lake, Ziegler, & Murphy, 1977; Launay et al., 1987;
Leboyer et al., 1994; Leventhal, Cook, Morford, Ravitz, & Freedman, 1990); two other
studies yielded null results (Herault et al., 1994; Martineau et al., 1994). These findings of
elevated NE were initially dismissed as a byproduct of heightened acute stress response to
venipuncture in children with ASD (Cook, 1990; Minderaa, Anderson, Volkmar, Akkerhuis,
& Cohen, 1994), and subsequent studies designed to address this issue used time-averaged
measures of NE-release (which are not affected by acute stress). Interestingly, the majority
of studies controlled in this manner yielded decreased time-averaged measures of NE release
and its metabolites (Barthelemy et al., 1988; Lake, et al., 1977; Martineau, Barthelemy,
Jouve, Muh, & Lelord, 1992; D. M. Young, Schenk, Yang, Jan, & Jan, 2010; J. G. Young,
Cohen, Brown, & Caparulo, 1978; J. G. Young, Cohen, Caparulo, Brown, & Maas, 1979).
Although the role of the NE-system in ASD had been de-emphasized by some (Cook, 1990;
Minderaa, et al., 1994), recent research has renewed interest in pursuing the topic of NE-
system functioning in ASD. This newer work includes findings of aberrant autonomic
function in ASD (Anderson & Colombo, 2009; Bal, et al., 2009; Giannotti, et al., 2008;
Ming, et al., 2005; Van Hecke, et al., 2009) and pharmacological studies showing positive
improvements in higher-order ASD symptomology following the administration of β-
adrenergic antagonists (e.g., propranolol; Beversdorf, Carpenter, Miller, Cios, & Hillier,
2008; Narayanan et al., 2010).
Salivary alpha-amylase (sAA)—In the current study we chose to examine a salivary
correlate of NE-system activation, alpha-amylase (sAA). sAA is a digestive enzyme that is
enriched with amylase, a salivary protein involved in the digestion of starches (Scannapieco,
Torres, & Levine, 1993). The release of sAA is stimulated by parasympathetic and
sympathetic innervations of α- and β-adrenergic receptors, leading to secretion of sAA from
the parotid salivary gland (Turner & Sugiya, 2002). In most studies (Chatterton, Vogelsong,
Lu, Ellman, & Hudgens, 1996; Rohleder, Nater, Wolf, Ehlert, & Kirshbaum, 2004;
Wetherell et al., 2000; but see Nater et al., 2006a) sAA has been found to be correlated with
diurnal (daytime) variations and basal levels (from a single resting measure) of NE, along
with phasic (task-specific) changes in plasma NE following the presentation of a physical or
psychological stressor. Although sAA has never been examined in conjunction with pupil
size, it has been found to vary with changes in other autonomic responses such as cardiac
(Bosch, de Geus, Veerman, Hoogstraten, & Amerongen, 2003; Nater, et al., 2006a) and
electrodermal activity (El-Sheikh, Erath, Buckhalt, Granger, & Mize, 2008). Furthermore,
like plasma NE, sAA decreases in response to β-adrenergic blockers (van Stregeren,
Rohleder, Everaerd, & Wolf, 2006) and increases in response to α2-adrenergic antagonists
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(Nater et al., 2006b). These findings provide support for sAA as an indirect estimate of NE-
system activation within the ANS (Nater & Rohleder, 2009).
Based on the difficulties associated with the venipuncture necessary for obtaining plasma
levels of NE in children with ASD, the collection of sAA affords a number of important
advantages. Correlates such as sAA have the potential to provide early and non-invasive
biomarkers of ASD, and have the potential to substantially impact our knowledge of the
underlying neural systems in ASD due to the link among sAA and ANS central NE-system
pathways.
Finally, because previous findings of dysregulated NE in ASD had been attributed to a stress
response arising from data collection procedures, we also included a measure of cortisol to
provide an independent assessment of stress in response to the current study procedures.
This enabled us to determine if sAA concentrations and tonic pupil size were affected by
aversion to the testing environment and/or collection method, or if sAA and tonic pupil size
are in fact accurate and viable indicators of altered ANS activation.
Current Studies
In this report we describe examinations of tonic pupil size, sAA, and cortisol in two
independent samples. In Study 1 we examined single afternoon levels of sAA and cortisol
taken at the laboratory and tonic pupil size in a small sample of children with ASD, along
with clinical and typically-developing (TD) age-matched controls. In Study 2 we sought to
replicate the findings of Study 1 with a larger sample of children with ASD compared to TD
age-matched controls, and extended this examination to include diurnal variations of sAA
taken at various time-points throughout the day in the child’s home environment to provide
a more comprehensive investigation of sAA levels. Due to differences in the control subjects
and measurement method we have reported on the samples separately, but we have also
included an aggregated analysis of tonic pupil size and afternoon sAA from both studies
comparing ASD and TD samples in an attempt to evaluate the discriminate ability of these
measures with a larger sample size.
STUDY 1
Method
Participants—Children between the ages of 20 to 72 months of age were recruited for this
study if they had a diagnosis of Autistic Disorder (AD), Pervasive-Developmental Disorder-
Not Otherwise Specified (PDD-NOS), Down Syndrome (DS), or if they were typically-
developing (TD). Children were recruited through mail from a variety of developmental
disability organizations in metropolitan and suburban areas of Kansas City, KS and MO, and
through a pre-established commercial list of families. Using this criterion, 37 children were
recruited and seen for testing appointments and data from 32 participants were used in the
final analysis for Study 1. Participants were given $50 per session ($100 total) to
compensate for time and travel.
Exclusion/attrition criteria: Children were excluded from participation if they had
impairments in vision and/or motor functioning that could significantly impede their ability
to participate in the testing session (e.g., severe vision loss or inability to sit upright without
assistance). With the exception of the ASD or DS diagnosis, none of the children had a
history of chronic illness or medication use (i.e., none of the children were chronically
taking any prescription or over-the-counter medications); the only exception to this was
seasonal allergies and occasional anti-histamine use (n = 8). All children who participated in
the current study were healthy (i.e., did not have any symptoms of acute illness such as cold,
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flu, allergies, etc.) and were medication-free at least 48 hours prior to the testing sessions
(i.e., those that were taking anti-histamines were asked to refrain from use for at least 48
hours and participated while they did not have allergy symptoms). Data from three
participants was unusable due to inaccurate or insufficient calibration during both testing
sessions, and two children were excluded because of the group-matching strategy.
Group assignment: The Autism Spectrum Disorder (ASD, n = 12) group consisted of
children who were formally given a diagnosis of either AD (n = 8) or PDD-NOS (n = 4) by
established diagnostic clinics in the Kansas City area that include teams of licensed
professionals who have been formally trained and certified to provide an official diagnosis
along the ASD spectrum. Diagnosis was verified by a trained member of our laboratory
through Autism Diagnostic Observation Schedule-Generic (ADOS-G; Lord, Rutter, &
DiLavore, 1997) administration of Module 1 or 2 (this was based on the child’s verbal
ability). Both ADOS-G Modules utilize a semi-structured play observation designed to
provide an opportunity to observe the presence or absence of the core deficits of AS and
PDD-NOS.
The age and gender composition of the ASD group dictated the recruitment and formation of
the DS and TD control groups. A one-way univariate ANOVA indicated no between-group
differences on chronological age (CA), F(2, 29) = .129, p = .879, η2 =.009, indicating that
the three groups were statistically matched on this variable. As expected, the groups varied
significantly on mental age (MA), based on the Mullen Early Learning Composite Score
(Mullen, 1995), F(2, 29) = 16.785, p < .001, η2 =.537. A one-way MANOVA was also
conducted to examine between-group differences in four subscale age-equivalents on the
Mullen (Visual Reception, Fine Motor, Receptive Language, and Expressive Language);
significant between-group differences were found among the four subscales of the Mullen,
Wilk’s Λ= .287, F(8, 42) = 4.552, p < .001, η2 =.464, with each of the subscales showing
significant between-group differences (all ps < .05). Follow-up comparisons of MA and
Mullen subscales are presented with each control group’s description below.
The DS (n = 9) group consisted of children with a pre-established diagnosis that was
independently verified by a genetics laboratory at birth, without a comorbid ASD diagnosis;
this was confirmed by a trained member of our laboratory through ADOS-G Module 1 or 2
administration. The DS group was matched with the ASD group on CA (p = .791), MA (p
= .714), subscale equivalents on the Mullen (all ps > .10), and gender distribution. The TD
group (n = 11) was comprised of children who had scores on all subscales of the Mullen not
less than one standard deviation below the test mean, and who did not have a diagnosed
developmental disability. The TD group was matched with the ASD group on CA (p = ns),
and gender distribution, χ2(2) = ns, but not on MA (p < .001) or Mullen subscales (all ps < .
05). None of the children in the TD or DS groups had a biological parent or sibling with a
diagnosis of ASD or other mental health issues such as schizophrenia, cognitive and
language delays. See Table 1 for age, gender, and demographic information for each group.
Testing Sessions—Participants were seen at the laboratory for two testing sessions
conducted at the same afternoon time (between 12:00 and 5:00 pm) on 2 different days (the
difference in data collection times from Day 1 to Day 2 was quite small, M = 11.35 minutes)
to ensure that differences were not due to diurnal variations, as sAA and cortisol are less
stable during morning hours (Nater, Rohleder, Schlotz, Ehlert, & Kirschbaum, 2007;
Rohleder, et al., 2004). Study appointments were scheduled to be approximately one to two
weeks apart (M = 14.04 days between sessions). Participants did not consume any
caffeinated products within two hours, no food or milk (or other protein-enhanced products)
within one hour, and no liquids within 10 minutes of their scheduled sessions to avoid
interference with salivary collection (Granger, Kivlighan, El-Sheikh, Gordis, & Stroud,
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2007; Hanrahan, McCarthy, Kleiber, Lutgendorf, & Tsalikian, 2006). Furthermore,
appointments were scheduled on typical days that were free of stressful or atypical events
(e.g., first day of school, birthday party, loss of a favorite toy, car wreck etc.) and parents
were asked to reschedule their appointments if any unusual or stressful events occurred.
Parents were also asked to keep their child inactive and ensure that their child did not
engage in any substantial physical activity (e.g., running, biking, swimming, etc.) at least 1 h
prior to the testing sessions; participants were reported to last engage in physical activity
between 1.5 and 48 hours prior to the testing sessions (M = 12.63 hours). Parent
confirmation of compliance with these restrictions was confirmed prior to the start of each
session.
Tonic Pupil Size and Laboratory Saliva Sample Collection: During each testing session
children were presented with a blank grey slide (3.0 lx) for three minutes to allow adequate
time to collect tonic pupil size and a single afternoon measure of sAA and cortisol; thus the
blank slide allowed us to obtain an un-stimulated or non-phasic measure of pupil size and
saliva concentrations. Tonic pupil size was obtained during the first minute of the blank grey
slide presentation, and saliva was collected during minutes 2 – 3 of the slide presentation.
The luminance of the slide was measured using a hand-held photometer under the same
distance and ambient conditions that were used during testing (see apparatus section).
Luminance readings were taken repeatedly during study set-up to ensure accuracy and
stability of measurement, and were checked regularly once data collection began to ensure
that set luminance levels were maintained.
Tonic pupil size: To ensure an accurate “resting” pupil measure, experimenters and parents
were asked to remain silent and not interact with the child during the first minute of slide
presentation when tonic pupil size was being obtained. Parents were allowed to be in the
room with the child but siblings were not. If the parent remained in the testing room, they
were required to stay behind a partition where they could see their child on the television
monitor but their child could not see or interact with them. The child was also unable to see
the experimenter.
Laboratory saliva sample collection: While the parent was completing paperwork a
“practice” saliva sample was taken from the child in the standardized testing room to
familiarize them with the collection procedure; this practice procedure was done on both
testing days. A single afternoon measure of salivary cortisol and sAA were taken one minute
after the start of the blank grey slide by simultaneously placing three Sorbettes (provided by
Salimetrics, LLC) under the child’s tongue for approximately two minutes. To minimize
disturbance of the child during saliva collection, the experimenter discretely obtained
samples by standing to the side and out of the child’s line of view and minimized their
interactions with the child. Sorbettes were then placed into 2 mL cryovials and immediately
frozen at -20° C. All samples were sent to Salimetrics to be assayed.
Apparatus: The stimulus was presented on a 40.6 cm computer monitor, which subtended a
21.6° visual angle at the viewing distance. Pupillary responses were recorded using an
Applied Science Laboratory (ASL) E6 eye-tracking system, Model 504 (ASL, 2008) with
the GazeTracker interface program (Eye-Gaze Response Interface Computer Aid, 2001)
setup in a darkened interior room. The pan/tilt module, a component of the ASL system,
uses infrared technology to illuminate the eye and telephoto an image of the eye onto an eye
camera. The E6 control unit then extracts the pupil and reflection of the light source on the
cornea and computes pupil diameter at a sampling rate of 60 Hz.
Each child was secured in a child-sized car seat using a five-point restraint to ensure the
child’s safety and to minimize movement (i.e., the child was unable to move forward or
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backward to control for accommodation efforts). The car seat was secured onto a hydraulic
chair, which enabled adjustment of the child’s eye height to be approximately centered with
the mid-point of the stimulus monitor (124.5 cm). The car seat was slightly reclined to
minimize head movement.
Data Extraction and Reduction
Tonic pupil size: Traces of pupil data that occurred within the screen coordinates (on the
screen) for the first minute of the blank grey slide presentation was inspected and corrected
for artifacts (blinks, loss of tracking, partial eyelid closures, head movements, and
accommodation responses) using linear interpolation. Artifacts were identified as (a) a time
difference between data points that were greater than 20 ms, (b) a discontinuity in pupil data,
represented by a 0-value in the data file, or (c) a difference in pupil size that was greater than
0.20 mm. Each pupil trace included in the final analysis was at least 500 ms in length, with
artifacts no longer than 500 ms and not exceeding 20% of the duration of the entire trace. An
average pupil size (tonic pupil size) was computed from the corrected trace during minute-1
of the blank grey slide presentation (i.e., pupil data from the last two minutes of the baseline
slide were not used) for both testing days. These artifact removal and average score
computation methods are similar to those used in several previous studies (Granholm,
Asarnow, Sarkin, & Dykes, 1996; Steinhauer, Siegle, Condray, & Pless, 2004; Verney,
Granholm, & Marshall, 2004). Because luminance was held constant (3.0 lx) across both
days for all groups, no data corrections were needed to adjust for changes in luminance as
there were none.
Laboratory saliva data: Concentrations of sAA (U/mL) were subjected to square root
transformations and cortisol concentrations (ug/dL) were subjected to a logarithm
transformation to adjust for positive skew and variability, as in previous salivary studies
(Fortunato, Dribin, Granger, & Buss, 2008; Gordis, Granger, Susman, & Trickett, 2006;
Granger, et al., 2007).
Data Analysis
Tonic pupil size and afternoon measures of sAA and cortisol were first analyzed for effects
of measurement order by evaluating within-group differences and interclass correlation
coefficients (ICC) and Cronbach’s Alpha reliability statistics to assess response stability
between Day 1 and Day 2. Because pupil and salivary measures from both testing days were
necessary to evaluate within-group differences, the sample size for these analyses are
smaller than that of the subsequent between-group analyses (six subjects had data for only
one testing session). Prior to data analysis, univariate outliers were identified; using a
criterion of scores greater than 4 SD from the group mean, three outliers for tonic pupil size
(two for afternoon sAA and one for afternoon cortisol) were identified and removed.
Because the age range of the current study had a fairly wide span (20 to 72 months of age)
between-group differences in all pupil and afternoon saliva measures taken at the laboratory
were evaluated with an ANCOVA, with CA entered as a covariate. To ensure that the
ANCOVA met the homogeneity assumption, homogeneity of the variance-covariance
matrices were evaluated at the p < .05 level using Levene’s estimate and were found to be
non-significant for all analyses in Study 1. Follow-up analyses were evaluated using the
LSD adjustment for multiple comparisons.
Results
Tonic Pupil Size—Within-group differences and ICCs among tonic pupil size, measured
during appointment Day 1 and Day 2, were first examined. The results of the paired-samples
t-test was non-significant, t(22) = -.699, with satisfactory ICCs, r = .774, and reliability,
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alpha =.87; thus, tonic pupil size from both testing days was averaged to form one variable.
A univariate Diagnosis (3) ANCOVA (controlling for CA) was then performed to evaluate
between-group differences in tonic pupil size, and was significant, F(2, 25) = 6.244, p = .
006, η2 = .333. Follow-up analyses of the Diagnosis main effect indicated that the ASD
group had a larger adjusted mean tonic pupil size (Madj = 5.593) that varied significantly
from the adjusted means of the DS (Madj = 4.199, p = .003) and TD (Madj = 4.535, p = .018)
groups (whose tonic pupil size did not differ significantly, p = .447). We also found a strong
correlation among tonic pupil size and total ADOS-G scores, r(25) = .490, p = .013. These
results replicate the Anderson and Colombo (2009) study of an enlarged tonic pupil size in
ASD, and demonstrate that the larger tonic pupil size in ASD is independent of CA. See
Figure 1 for observed means of tonic pupil size.
Afternoon Saliva Measures—Within-group differences and ICCs for sAA and cortisol
measurements, taken at one afternoon time point during Day 1 and Day 2 appointments,
were also examined. The results of the paired-samples t-test was non-significant for both
sAA, t(24) = -.845, p = ns, and cortisol, t(23) = 1.650, p = ns; the ICCs and reliability
statistics were satisfactory for both sAA (r = .808, alpha = .893) and cortisol (r = .434, alpha
= .451), therefore saliva measures from both testing days were averaged together for final
analyses.
Afternoon sAA: The univariate Diagnosis (3) ANCOVA (with CA held constant) for
between-group differences in afternoon levels of sAA revealed a significant main effect of
Diagnosis, F(2, 28) = 3.420, p = .047, η2 = .196. Follow-up analysis of the Diagnosis main
effect indicated that the adjusted mean of the ASD group (Madj = 6.444) was significantly
lower than the adjusted mean of the DS (Madj = 8.783, p = .050) and TD groups (Madj =
9.002, p = .025); the afternoon sAA levels of these two latter groups did not differ
significantly (p = .852). Furthermore, a significant negative correlation was found between
afternoon sAA and tonic pupil size, r(26) = -.462, p = .013; this correlation became non-
significant if diagnosis was held constant, rab.c(25) = -.205, p = .296, indicating that lower
afternoon levels of sAA and the larger tonic pupil size of the ASD group is likely driven by
a common underlying factor. Afternoon sAA levels were also significantly correlated with
ADOS-G total scores, r(27) = -.484, p = .011.
Afternoon salivary cortisol: The univariate Diagnosis (3) ANCOVA (covarying CA) to
examine between-group differences in afternoon cortisol revealed a significant main effect
of Diagnosis F (2, 28) = 4.382, p = .022, η2 = .238. However, this significant main effect
was driven by a higher adjusted mean afternoon cortisol level for the DS group (Madj =
-2.202), which differed significantly from the adjusted mean of the ASD (Madj = -2.708, p
= .038) and TD groups (Madj = -2.888, p = .007); the afternoon cortisol levels of the latter
two groups did not differ (p = .422). As expected, the correlation between afternoon cortisol
and tonic pupil size was non-significant, r(24) = -.102, p = ns, and remained non-significant
if diagnosis was partialed rab.c(23) = -.219, p = ns. The observed and adjusted means for
afternoon cortisol are negative values because they were subjected to a logarithm
transformation to adjust for positive skew and variability for analysis, but the pre-
transformed mean cortisol concentrations (ug/dL) are positive and presented in Figure 2.
Gender—Because the gender distribution of this sample was imbalanced, the above
analyses were also examined with the female participants excluded to ensure that the overall
results were not affected by the inclusion of females. When female participants were
removed from the analyses, the results were unchanged; the univariate Diagnosis (3)
ANCOVA retained significant between-group differences in tonic pupil size, F(2, 21) =
Anderson et al. Page 8













4.499, p = .024, η2 = .300, afternoon sAA, F(2, 23) = 7.899, p = .002, η2 = .407, and
afternoon cortisol levels, F (2, 21) = 7.648, p = .003, η2 = .421.
Classification of Group Membership—The above group-based analyses indicate that
both tonic pupil size and afternoon levels of sAA significantly differentiated the ASD group
from both DS and TD controls. Afternoon measures of sAA were included in the current
study as a means to investigate underlying neural functioning within the pupillary system,
but we chose to include both tonic pupil size and afternoon sAA in a discriminant analysis to
determine if the addition of afternoon levels of sAA would provide stronger discriminant
ability than tonic pupil size alone. The overall Wilks’ lambda was significant, Λ = .487, χ2
(4, N = 28) = 17.630, p = .001, with a non-significant residual, Wilks’ lambda, Λ = .951, χ2
(1, N = 28) = 1.226, p = ns, thus only the first discriminant function will be interpreted. The
discriminant analysis correctly classified 64.3% of the overall sample (53.6% cross-
validated), producing a 20% false-positive and 30% false-negative rate to detect ASD.
Specifically, we observed 80% correct classification (70% cross-validated) for the ASD
group, 66.7% (55.6% cross-validated) for the DS group, and 44.4% (33.3% cross-validated)
for the TD group. Table 2 presents the within-group correlations and standardized weights,
and Figure 3 presents a scatterplot of tonic pupil size and afternoon sAA levels.
Discussion
In Study 1 we observed enlarged tonic pupil size and lower afternoon levels of sAA to
significantly distinguish the ASD group from DS and TD controls. We then chose to
replicate and extend these findings in an independent sample of children with ASD to
address some of the limitations of Study 1. In Study 2, we measured tonic pupil size and
afternoon sAA and cortisol measures in the laboratory, in addition to diurnal variations of
sAA taken in the home environment at four time points across two days to ensure response
stability, in a larger sample of only males with ASD along with age-matched TD controls.
Because ICCs indicated response stability in tonic pupil size and afternoon sAA and cortisol
measures in Study 1 we chose to take only one laboratory measurement of each in Study 2.
Consequently, the methods employed in Study 2 were similar to those used in Study 1; for
brevity the reader will be referred to information in the Study 1 Method section where




Participants—Male children between the ages of 33 to 79 months of age were recruited
for Study 2 if they had a diagnosis of AD, PDD-NOS, or if they were TD. Thirty-seven
children were recruited using methods described above for Study 1 and were seen for one
testing appointment. Participants were given $50 for completing home saliva samples and
$40 for attending one laboratory session ($90 total) to compensate for time and travel.
Exclusion/attrition criteria: The exclusion criteria described in Study 1 was applied to the
recruitment of children in Study 2; none of the children were taking any chronic or acute
medications and all were free of any comorbid impairments.
Group assignment: The ASD group (n = 18) group consisted of children who were
formally given a diagnosis of either AD (n = 11) or PDD-NOS (n = 7) by established ASD
diagnostic clinics, which was confirmed through ADOS-G administration of Module 1 or 2
(based on the child’s verbal ability). The age of the ASD group dictated the recruitment and
formation of the TD group (n = 19). A one-way univariate ANOVA indicated no between-
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group differences on CA, F(1, 35) = 2.052, p = .161, η2 =.055, or MA, F(1, 35) = 2.053, p
= .161, η2 =.055, indicating that the two groups were statistically matched on both variables.
A one-way MANOVA was conducted to examine between-group differences in the four
subscale age-equivalents on the Mullen; a significant main effect of Diagnosis was found,
Wilk’s Λ= .638, F(4, 32) = 4.538, p < .01, η2 =.362; follow-up tests revealed significant
between-group differences on the Expressive Language subscale (p = .016) with the ASD
group having a lower mean MA (M = 45 m) than the TD group (M = 59 m), none of the
other Mullen subscales varied significantly between the groups (ps > .05). None of the
children in the TD group had a biological parent or sibling with a diagnosis of ASD or other
mental health issues such as schizophrenia and/or cognitive and language delays. See Table
3 for age and demographic information for both groups in Study 2.
Testing Sessions—Upon enrollment in Study 2, parents were sent a kit to obtain diurnal
variations in sAA from their child in the home environment at four pre-specified time
points; this was completed on two separate days to ensure response stability (see section
below on Diurnal Variations for sAA). Once both home samples were completed, one
afternoon laboratory session was scheduled (between 12:00 and 5:00 pm) to obtain tonic
pupil size and an afternoon sample of sAA and cortisol. Parents were asked to ensure that
their child adhered to the food, liquid, caffeine, and physical activity restrictions outlined in
the Testing Sessions section presented in Study 1; they were asked to adhere to these
restrictions for both diurnal sAA collection days and the laboratory session. Parents were
also instructed to collect the diurnal sAA samples and attend the laboratory session on
“typical” days that were free of stressful or atypical events, and were asked to reschedule
their home collection days and/or laboratory appointment if any unusual or stressful events
occurred. Parent confirmation of compliance with these restrictions was confirmed via
questionnaire for all three testing days (two home days and one laboratory session).
Diurnal sAA Variations: Parents were sent a salivary collection kit that contained (a) an
instruction sheet with detailed instructions and diagrams on how to properly collect and
store saliva samples in addition to our lab contact information, (b) collection supplies that
included eight Salimetrics Collection Swabs (SCS), eight cryovials, two storage bags, and
(c) a questionnaire to document the child’s current health, food intake, and stress levels for
each of the two collection days, along with collection times. Parents were instructed to
collect saliva samples at the following pre-determined times: 1) upon waking, 2) 30 minutes
after waking 3), at 11:50 am, and 4) at 4:50 pm. Once collected parents were instructed to
record the exact time the sample collection began on the questionnaire and indicate the
corresponding cryovial number. Parents were instructed to immediately place the collected
saliva sample in their home freezer. Once both collection days were completed (M = 10 days
between collection days), one afternoon laboratory session was scheduled (M = 24 days
between last home collection date and laboratory session date). Parents were asked to bring
the frozen saliva samples with them in a cooler to their scheduled appointment. Once they
arrived, the samples were immediately placed in our laboratory freezer and frozen at -20° C,
until they were sent to Salimetrics, LLC.
Laboratory Measurement of Tonic Pupil Size and Afternoon sAA and Cortisol: The
collection of tonic pupil size and afternoon measurement of sAA and salivary cortisol was
identical to the methods from Study 1; the only exception to this was that both measures
were only recorded on one testing day instead of two (see the Tonic Pupil Size and
Laboratory Saliva Sample Collection section from Study 1 for methodology). In the
following section, methods were identical to Study 1 unless otherwise specified.
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Afternoon saliva collection: The session began with a “practice” saliva sample even though
the children were familiar with the saliva collection method from the home samples that
were previously obtained by their parents; thus, Study 2 subjects did have more exposure to
the collection method than those in Study 1. The saliva sample was collected by placing one
SCS under the child’s tongue for approximately two minutes (the use of Sorbettes was
discontinued by Salimetrics between the conduct of the two studies, but the two collection
devices provide identical assay results).
Apparatus: The stimulus was presented and tonic pupil size was recorded using the same
apparatus, visual angle, interface program, sampling rate, and subject seating arrangement as
described in Study 1. The only exception to this was the incorporation of a video head
tracker (VHT) in Study 2 that is integrated into the ASL pan/tilt module and allows for auto-
detection of the child’s facial features to automatically find the child’s eye. The VHT
therefore decreases calibration time and allows for more precise tracking of the child’s eye
and head movements.
Data Extraction and Reduction
Tonic pupil data: Traces of pupil data that occurred within the screen coordinates for the
first minute of the blank grey slide were inspected and corrected for artifacts using the same
criteria outlined in Study 1, and an average tonic pupil size was computed from adequate
pupil traces.
Salivary data: Concentrations of sAA (U/mL) were subjected to square root
transformations, and cortisol concentrations (ug/dL) were subjected to a logarithm
transformation to adjust for positive skew and variability.
Data Analysis
Prior to data analysis univariate and multivariate outliers were identified using the criterion
of scores greater than 4 SD from the group mean and Mahalanobis distance at p < .001.
respectively; no outliers were found for tonic pupil size or afternoon cortisol measures taken
at the laboratory, but one outlier in the ASD group and two in the TD group for afternoon
sAA obtained at the laboratory, and two in the ASD group and one in the TD group for
diurnal sAA were identified and removed. As in Study 1, between-group differences in tonic
pupil size and measures of sAA and salivary cortisol from the laboratory session, and
diurnal sAA measures were evaluated using an ANCOVA, with CA entered as a covariate.
In addition, all analyses were evaluated for violations of homogeneity assumptions using the
Levene’s estimate at the p < .05 level; this assumption was not violated unless specified.
Results
Tonic Pupil Size—A univariate Diagnosis (2) ANCOVA again demonstrated a significant
between-group difference in tonic pupil size, F (1, 34) = 31.112, p > .001, η2 = .478, with
the ASD group having a significantly larger adjusted mean tonic pupil size (Madj = 5.573)
than the TD group (Madj = 4.304). We also observed a significant correlation among tonic
pupil size and ADOS-G total scores, r(37) = .526, p = .001, replicating the results obtained
in Study 1 and the Anderson and Colombo (2009) study. Taken together, these results
demonstrate a larger tonic pupil size in three independent samples of children with ASD.
See Figure 4 for observed means of tonic pupil size.
Laboratory Afternoon Saliva Measures
sAA: The homogeneity of variance was violated (p < .05) for this variable therefore, the
Welch’s variance-weighted ANOVA was used. This analysis revealed a significant main
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effect of Diagnosis, [Welch’s F (1, 19.258) = 17.843, p < .001, η2 = .332], with the adjusted
mean of the ASD group (Madj = 8.070) being significantly lower than the adjusted mean of
the TD group (Madj = 12.985). Correlations among afternoon sAA levels and ADOS-G total
scores were significant, r(34) = -.476, p = .004. As in Study 1, a significant and sizeable
negative correlation was also found between afternoon sAA and tonic pupil size, r(32) = -.
404, p = .018, which became non-significant once diagnosis was held constant, rab.c(31) = .
034, p = .853. These findings provide replication of those obtained in Study 1,
demonstrating lower afternoon levels of sAA taken in the lab environment in two
independent samples of children with ASD that is negatively correlated with tonic pupil
size.
Cortisol: The univariate Diagnosis (2) ANCOVA revealed no significant between-group
differences in afternoon cortisol measures, F (1, 34) = .513, p = .479, η2 = .015, (ASD, Madj
= -2.353; TD, Madj = -2.472), replicating the results obtained in Study 1. See Figure 5 for
pre-transformed mean concentrations of both laboratory measures of afternoon sAA (U/mL)
and salivary cortisol (ug/dL).
Diurnal sAA Variations—Because parents were allowed to choose the two collection
days, the saliva samples were collected on both weekdays and weekends. Therefore,
correlations among weekend versus weekday variations in home sAA levels were examined
and revealed non-significant correlations for each of the four pre-specified collection times
during Day 1 and Day 2 (ps > .05). Next, within-group differences and ICCs during
collection Day 1 and Day 2 were examined; the results of the paired-samples t-tests were
non-significant for all four sampling times (ps > .05), with satisfactory ICCs, r = .913 and
reliability, alpha = .93. As a result, diurnal sAA levels from both home testing days were
averaged together for each of the four time points.
The repeated measure ANCOVA for between-group differences in diurnal sAA variations in
the home environment revealed a significant main effect of Diagnosis, F (3, 30) = 3.126, p
= .040, η2 = .238. Follow-up polynomial contrasts indicated a significant linear effect F(1,
32) = 7.138, p = .012, partial η2 = .182. As can be seen in Figure 6, the diurnal sAA levels of
the TD group significantly increased over time (ps <.05), while those of the ASD group
remained unchanged (ps > .05) in the home environment.
Classification of Group Membership—As in Study 1, group-based analyses indicated
that tonic pupil size and afternoon sAA levels obtained during the laboratory session
significantly differentiated the ASD group from the TD group; in addition, Study 2 yielded
significant between-group differences in diurnal sAA variations from the home
environment. The next step was to conduct a discriminant analysis to determine whether we
could correctly classify ASD using tonic pupil size and afternoon sAA as in Study 1, and to
determine if the addition of diurnal sAA levels would increase the overall discriminate
ability of the model. The Wilks’ lambda for the analysis was significant, Λ = .279, χ2 (6, N =
37) = 21.707, p = .001, diagnostic group classification was successfully predicted for 91.9%
of the overall sample (78.4% cross-validated), yielding a 16% false-positive rate and a 0%
false-negative rate to detect ASD. Specifically, we observed 83.3% correct classification
(66.7% cross-validated) for the ASD group and 100% (89.5% cross-validated) for the TD
group. These classification results replicate and extend our findings from Study 1 and
demonstrate that the addition of diurnal sAA rhythms taken throughout the day in the home
environment provide an added benefit to the overall discriminant model, decreasing the
number of false negatives from 30% to 0%. Table 4 presents the within-group correlations
and standardized weights.
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Combined Results from Studies 1 and 2
Although the data for Studies 1 and 2 were collected under differing circumstances the
methods used to obtain tonic pupil size and afternoon sAA levels in the laboratory
environment were essentially the same. Therefore, we conducted an aggregate analysis using
the ASD and TD participants from both studies to provide overall analyses and determine
the degree of improved discrimination with the entire sample on hand.
Tonic Pupil Size and Afternoon sAA—As expected, a univariate Diagnosis (2)
ANCOVA (with CA entered as a covariate) yielded a significant between-group difference
in tonic pupil size, F (1, 54) = 38.776, p > .0001, η2 = .418. The ASD group (n = 29) had a
significantly larger adjusted mean tonic pupil size (Madj = 5.612) than the TD group (n = 28;
Madj = 4.347).
Similarly, a univariate Diagnosis (2) ANCOVA (with CA again entered as a covariate)
yielded a significant between-group difference in afternoon levels of sAA obtained during
the laboratory session, F (1, 49) = 6.041, p = .018, η2 = .110. The adjusted mean of the ASD
group (n = 27; Madj = 8.958) was significantly lower than the adjusted mean of the TD
group (n = 25; Madj = 11.963).
Classification of Group Membership—The discriminant analysis using the aggregated
samples from both studies was conducted using tonic pupil size and afternoon laboratory
obtained measures of sAA to classify ASD. The Wilks’ lambda was significant, Λ = .529, χ2
(2, N = 49) = 29.269, p < .001, and successfully predicted diagnosis for 85.7% of the overall
sample (83.7% cross-validated), producing a 19.2% false-positive rate and an 8.7% false-
negative rate to detect ASD. This yielded 80.8% correct classification (80.8% cross-
validated) for the ASD group and 91.3% (87% cross-validated) for the TD group.
Overall Discussion
Major Findings—The goal of the current study was to examine the potential for
biomarkers of ASD that might be obtained during infancy and may identify potential sources
of neurological dysfunction to address the priorities outlined by the CDC. Previous studies
have found dysregulated tonic pupil size in ASD (Anderson & Colombo, 2009; Anderson,
Colombo, & Shaddy, 2006; Fan, et al., 2009; Martineau, et al., 2011; Rubin, 1961). We
examined and replicated the dysregulated tonic pupil size in two independent samples of
children with ASD in the current study and extended this finding to include the
measurement of afternoon laboratory levels and home diurnal variations of sAA, which
provides a potential non-invasive measure of NE-mediated regulation of pupil size. While
sAA may not be a perfect correlate of NE, it has been found in most studies to be correlated
with NE-system activity and the current findings showed it as a non-invasive stress-free
alternative to venipuncture in assessing NE activity. Owing to the fact that our
understanding of the sAA-NE connection is still not definitive, the results of the current
study should be interpreted with appropriate caution.
In both Study 1 and Study 2, the ASD group was significantly distinguished from controls
through a larger tonic pupil size and lower afternoon laboratory levels of sAA, and found to
be significantly related to tonic pupil size and ADOS-G scores. These results provide
replication of the larger tonic pupil size to a light stimulus (Anderson & Colombo, 2009) in
two independent samples of children with ASD, and provide further support for the precence
of dysregulated pupillary responses in ASD (Fan, et al., 2009; Martineau, et al., 2011). The
sAA results extend the pupillary findings and potentially implicate the involvement of the
NE component of the pupillary system in producing this response. The fact that, in both
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studies, salivary cortisol did not vary between ASD and TD groups suggests that afternoon
laboratory sAA results were not mediated by stress from data collection.
In addition, Study 2 revealed differences in diurnal patterns of sAA between ASD and TD
participants; sAA concentrations did not vary in the ASD group but the TD group showed
significant increases in sAA levels throughout the day.
Age Range of the Study—The 20 to 79 month age range was chosen for the current
study because this is currently the youngest age group that most researchers agree ASD can
be diagnosed using “gold standard” measures such as the ADOS-G (Chawarska, Klin, Paul,
& Volkmar, 2007; Cox et al., 1999; Lord et al., 2006), and was therefore the target age
group for the initial evaluation of potential biomarkers of ASD. Although this was a broad
age range, we controlled for age by matching the groups on CA and MA, and by entering
age as a covariate in the analyses.
Cortisol Findings in Down Syndrome Controls—Finally, in Study 1, we
unexpectedly found the DS group to be distinguished from both the TD and ASD groups by
heightened tonic levels of salivary cortisol. It may be that the heightened salivary cortisol
response in the DS group could represent an increased risk for the co-occurrence of a variety
of chronic conditions such as suppressed growth or immune and inflammatory responses as
these conditions are commonly associated with increased cortisol levels (Charmandari,
Kino, Souvatzoglou, & Chrousos, 2003) and commonly occur in DS (Cronk et al., 1988;
Kusters, Verstegen, Gemen, & de Vries, 2009). While none of the DS participants in the
current study were reported to have any chronic conditions, these differential heightened
cortisol levels warrant further investigation.
Implications—The results of the current study have two primary implications. First
replication of a dysregulated tonic pupil size and altered sAA in ASD implicates their
potential as biomarkers for early identification. Second, both measures have the potential to
provide information about neurological development in ASD and could provide potential
targets for pharmacological intervention.
Potential influence of the NE-system in ASD: The NE-system is involved in a number of
processes found to be commonly impaired in ASD, such as resting and reflex ANS activity
(Anderson & Colombo, 2009; Bal, et al., 2009; Fan, et al., 2009; Ming, et al., 2005; Rubin,
1961; Van Hecke, et al., 2009), altered pain perception (Baranek & Berkson, 1994; Kientz &
Dunn, 1997), and decreased sleep-wake cycle activity (Honomichl, et al., 2002; Oyane &
Bjorvatn, 2005; Williams, Sears, & Allard, 2004). The early development of the NE-system
and vast NE innervations allow for fundamental influences in central nervous system (CNS)
development (Aston-Jones, Foote, & Bloom, 1984; Coyle, 1977; Foote, Bloom, & Aston-
Jones, 1983; Schlumpf, Shoemaker, & Bloom, 1980; Sievers, Lolova, Jenner, Klemm, &
Sievers, 1981), including cortical structures (Schlumpf, et al., 1980). Therefore, it is not
surprising that improvements in aggression, irritability, anxiety, self-injurious behaviors,
increased sleep time, task performance and working memory have all been found following
the administration of β-adrenergic antagonists such as propranolol in ASD (Beversdorf, et
al., 2008; Narayanan, et al., 2010), which reduces NE-modulated connections within cortical
regions responsible for higher-order processing of communication and social responsiveness
(Hasselmo, Linster, Patil, Ma, & Cekic, 1997).
Conclusion: If tonic pupil size and sAA do provide an indication of altered tonic ANS
functioning in ASD, then assessment of this system early in life could lead to a greater
understanding of how the pathology and functional impairment within this system may be
involved in the neural pathology of ASD and the resulting cognitive and behavioral
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symptomology. In addition, this knowledge may provide a target for pharmacological
remediation. Given the potential impact of the identification of early biomarkers of ASD, the
results of the current study emphasize the need to further evaluate tonic pupil size and sAA
as indicators of the disorder through replication with larger samples, and extension of these
findings to infants and young children, pre-diagnosis, to further evaluate the early
identification potential of tonic pupil size and sAA.
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Study 1, average observed mean tonic pupil size from both testing days for the Autism
Spectrum Disorder (ASD), Down syndrome (DS), and Typically-developing (TD) groups,
presented in the bar graph. Observed mean pupil size and standard error for each individual
subject, organized by group, presented in the scatterplot; the ASD group is separated by
Autistic Disorder (AD) and Pervasive Developmental Disorder-Not Otherwise Specified
(PDD-NOS).
**p < .025
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Study 1 mean afternoon laboratory concentrations of salivary alpha-amylase (sAA) and
cortisol for the Autism Spectrum Disorder (ASD), Down syndrome (DS), and Typically-
developing (TD) groups, presented in the bar graph. Mean concentrations and standard
errors for each individual subject, organized by group, are presented in the scatterplot; the
ASD group is separated by Autistic Disorder (AD) and Pervasive Developmental Disorder-
Not Otherwise Specified (PDD-NOS). The means are presented as the pre-transformed
concentrations of afternoon laboratory sAA and cortisol, but it was the square root and
logarithm transformations that were used in the respective analyses to adjust for positive
skew and variability.
** p < .025; * p < .05.
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Study 1, scatterplot of tonic pupil size to afternoon laboratory salivary concentrations of
alpha-amylase (sAA) for the Autism Spectrum Disorder (ASD), Down Syndrome (DS), and
Typically-developing (TD) groups.
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Bar graph for Study 2 displaying the average observed mean tonic pupil size for the Autism
Spectrum Disorder (ASD) and Typically-developing (TD) groups; observed mean tonic
pupil size and standard error for each individual subject is organized by group and presented
in the scatterplot. The ASD group is separated by Autistic Disorder (AD) and Pervasive
Developmental Disorder-Not Otherwise Specified (PDD-NOS).
***p < .001
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Study 2 mean afternoon laboratory concentrations of salivary alpha-amylase (sAA) and
cortisol for the Autism Spectrum Disorder (ASD) and Typically-developing (TD) groups,
presented in the bar graph. Mean afternoon salivary concentrations and standard error for
each individual subject is organized by group and presented in the scatterplot. The ASD
group is separated by Autistic Disorder (AD) and Pervasive Developmental Disorder-Not
Otherwise Specified (PDD-NOS). The means are presented as the pre-transformed
concentrations of afternoon sAA and cortisol, but it was the square root and logarithm
transformations that were used in the respective analyses to adjust for positive skew and
variability.
*** p < .001.
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Study 2 observed means of diurnal variations in salivary concentrations of alpha-amylase
(sAA) for the Autism Spectrum Disorder (ASD) and Typically-developing (TD) groups. The
means are presented as the pre-transformed concentrations of sAA, but it was the square root
transformations that were used in the respective analyses to adjust for positive skew and
variability.
*p < .05.
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Table 2
Study 1: Discriminant Analysis Coefficients for Prediction of Diagnosis
Predictor Correlation coefficient Standardized coefficientsa
Afternoon sAA .699 .745
Tonic pupil size .221 -536
Note. Afternoon sAA = baseline measures of salivary alpha-amylase (AA) taken across two testing days in the laboratory environment; Tonic pupil
size = baseline measures of pupil size, recorded across two testing days in the laboratory.
a
Standardized canonical discriminant function coefficients.
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Table 3
Study 2: Age and Demographic Information for Both Groups
ASD TD
n = 18 n = 19
CAa M Range M Range
57.78 39 - 73 52.26 33 - 79
MULLEN
 Visual Receptionab 48.89 8 - 69 52.05 29 - 69
 Fine Motorab 49.61 5 - 68 51.89 26 - 68
 Receptive Languageab 48.00 4 - 69 56.21 34 - 69
 Expressive Languageab 44.72 1 - 70 58.57 37 - 70
 Composite (MA)ab 47.81 4 - 66 54.68 32 - 68
ADOS-G
 Social 9.56 4 - 16 0
 Communication 8.69 2 - 24 0
 Behavior 4.22 1 - 7 0
Parent education levelc 11.33 4 - 17 13.05 9 - 19
Note. ASD = Autism Spectrum Disorder; TD = typically developing; CA = Chronological age. Mullen = Mullen Scales of Early Learning (Mullen,
1995); Composite = Early Learning Composite; MA = Mental age; ADOS-G = Autism Diagnostic Observation Schedule Generic (Lord et al.,






Years beyond high school for both parents
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Table 4
Study 2: Discriminant Analysis Coefficients for Prediction of Diagnosis
Predictor Correlation coefficient Standardized coefficientsa
Home Diurnal sAA Times
 Waking .321 .837
 30 min + Waking .043 -.351
 Afternoon -.115 .346
 Evening -.101 -.246
Laboratory Measures
 Afternoon sAA -.183 -.789
 Tonic pupil size .678 .910
Note. sAA = salivary alpha-amylase; Waking sAA = sAA taken across two testing days upon waking; 30 min + Waking sAA = sAA taken across
two testing days 30 minutes after waking time; Afternoon sAA = sAA taken across two testing days at 11:50 am; Evening sAA = sAA taken across
two testing days at 4:50 pm; Laboratory sAA = sAA taken during one afternoon laboratory session; Tonic pupil size = baseline measure of pupil
size taken during one afternoon laboratory session.
a
Standardized canonical discriminant function coefficients.
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